{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:38:32Z","timestamp":1768257512424,"version":"3.49.0"},"reference-count":23,"publisher":"Universa BV","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Background and study aims: Crohn\u2019s disease (CD) is often complicated by perianal fistulas or abscesses that worsen patient\u2019s quality of life, with 52-88% of CD-related perianal fistulas (CPFs) being complex. This retrospective study describes sociodemographic characteristics, treatment patterns and outcomes of patients with complex CPFs in five European countries.\n\nPatients and methods: PREFACE is a multi-national medical chart review study of CD patients who started medical or surgical treatment for a new episode of complex CPFs between September 2011 and September 2014 (index date). Effectiveness outcomes were assessed as fistula remission rates based on fistula drainage assessment. The most recent assessments prior to each timepoint were used to calculate fistula remission rates.\n\nResults: In total, 372 patients (51.3% male, mean age at index date 37.8 years) with 498 complex CPFs between index date and end of data collection were included. A quarter of patients with CPF already had perianal fistulas at CD diagnosis. Of the complex index CPFs, 39.8% were treated with antitumour necrosis factor, 33.3% with antibiotics and 16.3% with immunosuppressants. At least one surgery was performed for 93.8% of complex CPFs. By end of follow-up (median (IQR) 6.0 (5.2, 6.9) years), 61.2% of complex CPFs were not draining anymore. Fistula remission rate at patient level was 28.0% after 6 months, 35.2% after 12 months and 64.8% overall.\n\nConclusions: Current therapeutic algorithms for CPFs are not successful in a considerable proportion of patients. Improved therapeutic strategies and new treatment options are required to achieve better outcomes in complex CPFs.<\/jats:p>","DOI":"10.51821\/87.4.13143","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:55:00Z","timestamp":1736376900000},"page":"494-504","source":"Crossref","is-referenced-by-count":1,"title":["Treatment patterns and outcomes of patients with complex Crohn\u2019s perianal fistula in five European countries: the PREFACE study"],"prefix":"10.51821","volume":"87","author":[{"given":"M","family":"Ferrante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Siproudhis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Poggioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Reinshagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Milicevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Roset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"BentEnnakhil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Fernandez-Nistal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Panes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2024,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"MAYBERRY JF, LOBO A, FORD AC, THOMAS A. NICE clinical guideline (CG152): the management of Crohn\u2019s disease in adults, children and young people. Aliment Pharmacol Ther 2013; 37(2):195-203.","DOI":"10.1111\/apt.12102"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"GOMOLL\u00d3N F, DIGNASS A, ANNESE V, TILG H, VAN ASSCHE G, LINDSAY JO et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11(1):3-25.","DOI":"10.1093\/ecco-jcc\/jjw168"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"EGLINTON TW, BARCLAY ML, GEARRY RB, FRIZELLE FA. The spectrum of perianal Crohn\u2019s disease in a population-based cohort. Dis Colon Rectum 2012; 55(7):773-7.","DOI":"10.1097\/dcr.0b013e31825228b0"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"INGLE SB, LOFTUS EV. The natural history of perianal Crohn\u2019s disease. Dig Liver Dis 2007; 39(10):963-9.","DOI":"10.1016\/j.dld.2007.07.154"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"FIGG RE, CHURCH JM. Perineal Crohn\u2019s disease: an indicator of poor prognosis and potential proctectomy. Dis Colon Rectum 2009; 52(4):646-50.","DOI":"10.1007\/dcr.0b013e3181a0a5bf"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"COHEN RD, WATERS HC, TANG B, RAHMAN MI. Effects of fistula on healthcare costs and utilization for patients with Crohn\u2019s disease treated in a managed care environment. Inflamm Bowel Dis 2008; 14(12):1707-14.","DOI":"10.1002\/ibd.20530"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"LICHTENSTEIN GR, YAN S, BALA M, BLANK M, SANDS BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease. Gastroenterology 2005; 128(4):862-9.","DOI":"10.1053\/j.gastro.2005.01.048"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"SANDBORN WJ, FAZIO VW, FEAGAN BG, HANAUER SB. AGA technical review on perianal Crohn\u2019s disease. Gastroenterology 2003; 125(5):1508-30.","DOI":"10.1016\/j.gastro.2003.08.025"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"COLOMBEL J-F, SANDBORN WJ, RUTGEERTS P, ENNS R, HANAUER SB, PANACCIONE R et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 2007; 132(1):52-65.","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"BELL SJ, WILLIAMS AB, WIESEL P, WILKINSON K, COHEN RCG, KAMM MA. The clinical course of fistulating Crohn\u2019s disease. Aliment Phar- macol Ther 2003; 17(9):1145-51.","DOI":"10.1046\/j.1365-2036.2003.01561.x"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Panes J, Reinisch W, Rupniewska E, Khan S, Forns J, Khalid JM et al. Burden and outcomes for complex perianal fistulas in Crohn\u2019s disease: Systematic review. World J Gastroenterol 2018; 24(42):4821-34.","DOI":"10.3748\/wjg.v24.i42.4821"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease. Gut 2014; 63(9):1381-92.","DOI":"10.1136\/gutjnl-2013-306709"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"PREFONTAINE E, MACDONALD JK, SUTHERLAND LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2010; (6):CD000545.","DOI":"10.1002\/14651858.cd000545.pub3"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"PEARSON DC, MAY GR, FICK GH, SUTHERLAND LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123(2):132-42.","DOI":"10.7326\/0003-4819-123-2-199507150-00009"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"GIONCHETTI P, DIGNASS A, DANESE S, MAGRO DIAS FJ, ROGLER G, LAKATOS PL et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 2: Surgical Mana- gement and Special Situations. J Crohns Colitis 2017; 11(2):135-49.","DOI":"10.1093\/ecco-jcc\/jjw169"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"KELLEY KA, KAUR T, TSIKITIS VL. Perianal Crohn\u2019s disease: challenges and solutions. Clin Exp Gastroenterol 2017; 10:39-46","DOI":"10.2147\/ceg.s108513"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"SATSANGI J, SILVERBERG MS, VERMEIRE S, COLOMBEL J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55(6):749-53.","DOI":"10.1136\/gut.2005.082909"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"MOLENDIJK I, NUIJ VJAA, VAN DER MEULEN-DE JONG AE, VAN DER WOUDE CJ. Disappointing durable remission rates in complex Crohn\u2019s disease fistula. Inflamm Bowel Dis 2014; 20(11):2022-8.","DOI":"10.1097\/mib.0000000000000148"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"ARBERAS-DIEZ B, CHAPARRO M, BURGUE\u00d1O P, VERA I, BERMEJO F, MAR\u00cdN-JIM\u00c9NEZ I et al. P536 Effectiveness of the available therapeutic options in the treatment of perianal fistulas in patients with Crohn\u2019s disease (CD). Journal of Crohn\u2019s and Colitis 2013; 7:S225.","DOI":"10.1016\/s1873-9946(13)60557-7"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"VAN ASSCHE G, DIGNASS A, REINISCH W, VAN DER WOUDE CJ, STURM A, DE VOS M et al. The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: Special situations. J Crohns Colitis 2010; 4(1):63-101.","DOI":"10.1016\/j.crohns.2009.09.009"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"WASMANN KA, GROOF EJ DE, STELLINGWERF ME, D\u2019HAENS GR, PONSIOEN CY, GECSE KB et al. Treatment of Perianal Fistulas in Crohn\u2019s Disease, Seton Versus Anti-TNF Versus Surgical Closure Fol- lowing Anti-TNF PISA: A Randomised Controlled Trial. J Crohns Colitis 2020; 14(8):1049-56.","DOI":"10.1093\/ecco-jcc\/jjy222.107"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"PAN\u00c9S J, GARC\u00cdA-OLMO D, VAN ASSCHE G, COLOMBEL JF, REINISCH W, BAUMGART DC et al. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn\u2019s Disease. Gastroenterology 2018; 154(5):1334-1342.e4.","DOI":"10.1007\/s11725-017-0682-y"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"MOTAMEDI MAK, SERAHATI S, RAJENDRAN L, BROWN CJ, RAVAL MJ, KARIMUDDIN A et al. Long-term outcomes after seton placement for perianal fistulas with and without Crohn\u2019s disease. Colorectal Dis 2021.","DOI":"10.1111\/codi.15771"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:55:06Z","timestamp":1736376906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2203\/Treatment%20patterns%20and%20outcomes%20of%20patients%20with%20complex%20Crohn%E2%80%99s%20perianalfistula%20in%20five%20European%20countries:%20the%20PREFACE%20study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.51821\/87.4.13143","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}